I honestly think there is some serious misinterpretation going on. Although I don't know the full ramifications of not being in stage 2 (yet?), the fact that paxalisib reached full recruitment before other treatment arms means that it is outperforming the other treatment arms. That is how the recruitment is allotted in this study.